Compare TMHC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMHC | RYTM |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.8B |
| IPO Year | 2012 | 2017 |
| Metric | TMHC | RYTM |
|---|---|---|
| Price | $71.46 | $87.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $71.71 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 2.8M | 538.3K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $4,762,059,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $8.96 | $86.06 |
| P/E Ratio | $70.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.15 | $60.71 |
| 52 Week High | $72.27 | $122.20 |
| Indicator | TMHC | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 76.26 | 48.70 |
| Support Level | $56.84 | $87.19 |
| Resistance Level | $72.27 | $92.51 |
| Average True Range (ATR) | 1.04 | 3.44 |
| MACD | 1.70 | -0.48 |
| Stochastic Oscillator | 98.13 | 46.51 |
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.